Test Price
2,800 AEDโ Home Collection Available
PCDH15 Gene Sequencing (Autosomal Recessive Deafness Type 23, NGS) in UAE | AED 2,800 | DHA Licensed
Executive Summary & Core Metrics
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Processing
- Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (8 AM โ 11 PM)
- Clinical Guidance: Telephonic post-test clinical guidance with a DHA-licensed Consultant Medical Geneticist
- Insurance: Direct billing verification via WhatsApp at +971 54 548 8731
- UAE Legal Compliance: Fully compliant with Federal Decree-Law No. 45 of 2021 (PDPL) and Federal Law No. 2 of 2019 (ICT in Health)
Test Overview & Methodology
This test analyzes the PCDH15 gene using Next-Generation Sequencing (NGS) to detect mutations responsible for autosomal recessive deafness type 23 (DFNB23), a severe-to-profound congenital hearing loss. The comprehensive sequencing covers all coding exons and splice sites, enabling precise molecular diagnosis for cochlear implant candidacy and family planning. Accepted sample types include whole blood, extracted DNA, or one drop of blood on an FTA card.
| Feature | Our Test | Closest Alternative |
|---|---|---|
| Method | NGS (Full Gene Sequencing) | Sanger Sequencing (Single Variant) |
| Diagnostic Yield | >98% for DFNB23 | ~60% (targeted only) |
| Turnaround Time | 3โ4 Weeks | 2โ3 Weeks (limited scope) |
Physician Insight & Safety Protocols
โThe PCDH15 NGS test provides a definitive molecular diagnosis for autosomal recessive deafness type 23. It is essential for confirming the genetic etiology of prelingual hearing loss, guiding cochlear implant decisions, and enabling accurate genetic counseling. Results must always be correlated with audiological and vestibular assessments for comprehensive patient management.โ โ Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Pre-Test Advisory
Mandatory pre-test genetic counseling is required for all patients. This test should not replace urgent clinical evaluation for sudden hearing loss. Do not discontinue any prescribed otological or neurological medications without consulting your physician. The test is for diagnostic clarification only and does not alter ongoing treatments.
Exclusion Criteria
- Not for acute sudden sensorineural hearing loss โ seek emergency ENT evaluation immediately.
- Minors require parental or legal guardian consent as per UAE Federal Law No. 2 of 2019.
- Individuals with active ear infections or recent ear surgery should postpone sample collection.
- If result interpretation suggests syndromic hearing loss (e.g., Usher syndrome), urgent ophthalmology referral is warranted โ inform the lab immediately.
Patient FAQ & Clinical Guidance
1. What is the PCDH15 gene test and who should consider it?
This NGS-based test diagnoses autosomal recessive deafness type 23 by detecting mutations in the PCDH15 gene. It is suitable for infants and children with prelingual hearing loss of unknown cause, for families with a history of hereditary hearing loss, and for individuals being evaluated for cochlear implantation. The test identifies the exact genetic variant, confirms inheritance pattern, and guides personalized management.
2. How accurate is the NGS methodology for this hearing loss gene?
Our NGS technology covers the entire PCDH15 coding region with >99.9% sensitivity and specificity. It detects all mutation types, including missense, nonsense, frameshift, and splice-site variants, surpassing the limitations of targeted single-variant analysis. Detailed bioinformatics analysis ensures high-confidence variant calling.
3. What sample is required and how long do results take?
A whole blood sample (3โ5 ml in EDTA tube), extracted DNA (minimum 1 ยตg), or a single drop on an FTA card is acceptable. Results are delivered within 3โ4 weeks, including NGS processing, bioinformatics analysis, and a comprehensive clinical report reviewed by our DHA-licensed genetics team.
4. How do I arrange home sample collection?
Our VIP Mobile Phlebotomy service is available daily from 8 AM to 11 PM across Dubai and major UAE cities. Temperature-controlled cold-chain transport ensures sample integrity. Contact us via WhatsApp at +971 54 548 8731 to schedule a convenient time. Hospital extraction is not required for this test.
UAE Regulatory & Data Privacy Adherence
Data Protection & Legal Framework
This test operates under the strictest UAE health data regulations: Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Patient consent and safety are governed by Federal Decree-Law No. 4 of 2016 on Medical Liability. Our facility is ISO 9001:2015 certified (INT/EGQ/2509DA/3139) and holds DHA Facility License No. 1143. All genetic data is encrypted, anonymized, and stored within UAE borders.
Clinical & Logistical Metadata
| Test Name | PCDH15 Gene Sequencing (Autosomal Recessive Deafness Type 23, NGS) |
| Price (AED) | 2,800 |
| Turnaround Time | 3โ4 Weeks |
| Sample Type / Matrix | Whole Blood (EDTA), Extracted DNA, or FTA Card |
| Methodology Used | Next-Generation Sequencing (NGS) โ Full Gene Coverage |
| ICD-10-CM Code | H90.3 |
| LOINC Code | 93025-8 |
| DHA Facility License & Laboratory Address | DHA License 1143 | DNA Labs UAE, Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
ุฏุนู ุซูุงุฆู ุงููุบุฉ ู ุชุงุญ
ุงูุชุญูู ู ู ุงูุชุบุทูุฉ ุงูุชุฃู ูููุฉ
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
ุชููู ุนู ุงูุชุฎู ูู. ุฃุฑุณู ุตูุฑุฉ ู ู ุจุทุงูุฉ ุงูุชุฃู ูู ููุตูุฉ ุงูุทุจูุจ ุฅูู ูุฑูู ุงูุชุญูู ุงูู ุนุชู ุฏ ู ู ููุฆุฉ ุงูุตุญุฉ ุจุฏุจู ุนุจุฑ ุงููุงุชุณุงุจ. ุงุญุตู ุนูู ุชุญุฏูุซ ุงูุญุงูุฉ ูู ุฏูุงุฆู.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians